期刊
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
卷 142, 期 4, 页码 452-458出版社
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPIKDZM39CRPNC
关键词
T cells; Merkel cell carcinoma; Survival
类别
资金
- National Institutes of Health, Bethesda, MD [NIH-RC2CA147820, NIH-K24-CA139052, NIH-F30ES017385]
- American Cancer Society [RSG-08-115-01-CCE]
- Cora May Poncin Foundation
- MCC Patient Gift Fund
- David & Rosalind Bloom Fund
- Michael Piepkorn Endowment
Objectives: Intratumoral CD8+ lymphocytes (IT-CD8s) have shown promise as a prognostic indicator for Merkel cell carcinoma (MCC). We tested whether IT-CD8s predict survival among a population-based MCC cohort. Methods: One hundred thirty-seven MCC cases that had not previously been analyzed for IT-CD8s were studied. Results: Three-year MCC-specific survival rates were 56%, 72%, and 100% for patients with absent (n = 46), low (n = 85), and moderate or strong (n = 6) IT-CD8s, respectively. Increased IT-CD8s were associated with improved MCC-specific survival in a multivariate competing risk-regression analysis including stage, age, and sex (hazard ratio [HR] = 0.5; 95% confidence interval [CI] = 0.3-0.9). Although a similar trend was observed for overall survival, statistical significance was not reached (HR = 0.8; 95% CI = 0.6-1.0), likely because of the high rate of non-MCC deaths among older patients. Conclusions: This study of prospectively captured MCC cases supports the concept that cellular immunity is important in MCC outcome and that CD8+ lymphocyte infiltration adds prognostic information to conventional staging.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据